Southwest Oncology Group Trial S9912: intraperitoneal cisplatin and paclitaxel plus intravenous paclitaxel and pegylated liposomal doxorubicin as primary chemotherapy of small-volume residual stage III ovarian cancer.

Publication Type:

Journal Article

Authors:

Smith, Harriet O; Moon, James; Wilczynski, Sharon P; Tiersten, Amy D; Hannigan, Edward V; Robinson, William R; Rivkin, Saul E; Anderson, Garnet L; Liu, Ping-Yu; Markman, Maurie

Source:

Gynecologic oncology, Volume 114, Issue 2, p.206-9 (2009)

Keywords:

2009, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Cisplatin, Disease-Free Survival, Doxorubicin, Female, Humans, Infusions, Intravenous, Infusions, Parenteral, Middle Aged, Neoplasm Staging, Ovarian Neoplasms, paclitaxel, Polyethylene Glycols, Public Health Sciences Division

Abstract:

While primary cisplatin-based intraperitoneal chemotherapy has been shown to favorably impact survival in small-volume residual advanced ovarian cancer, there is a need to develop strategies that improve the effectiveness of this approach.